TRADING UPDATES: Clinigen signs Copiktra deal; Alien lse.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lse.co.uk Daily Mail and Mail on Sunday newspapers.
T3D Therapeutics, Inc.: T3D Therapeutics Announces First Patient Dosed in its Phase 2 Study of T3D-959 for the Treatment of Mild to Moderate Alzheimer s Disease
Research Triangle Park, 04/20/2021 EQS Newswire - T3D Therapeutics, Inc. RESEARCH TRIANGLE PARK, NC / ACCESSWIRE / April 20, 2021 / T3D Therapeutics, Inc. ( T3D ), a clinical stage drug development company engaged in the development of T3D-959, a new orally administered treatment for Alzheimer s disease (AD), announced today the initiation of dosing in a Phase 2 clinical study of neurometabolic regulator T3D-959 in patients with mild to moderate Alzheimer s disease, the PIONEER Study. T3D-959 is a small molecule, orally-delivered, brain-penetrating PPAR delta/gamma dual nuclear receptor agonist designed to improve both glucose and lipid metabolism dysfunctions present in AD, and other neurodegenerative disorders.
EQS-News: T3D Th .
EQS-News: T3D Therapeutics, Inc.: T3D Therapeutics Announces First Patient Dosed in its Phase 2 Study of T3D-959 for the Treatment of Mild to Moderate Alzheimer s Disease
vom 20.04.2021, 13:01 Uhr
Bild: pixabay.com
T3D Therapeutics, Inc.: T3D Therapeutics Announces First Patient Dosed in its Phase 2 Study of T3D-959 for the Treatment of Mild to Moderate Alzheimer s Disease
Research Triangle Park, 04/20/2021 / 07:01, EST/EDT - EQS Newswire - T3D Therapeutics, Inc.
RESEARCH TRIANGLE PARK, NC / ACCESSWIRE / April 20, 2021 / T3D Therapeutics, Inc. ( T3D ), a clinical stage drug development company engaged in the development of T3D-959, a new orally administered treatment for Alzheimer s disease (AD), announced today the initiation of dosing in a Phase 2 clinical study of neurometabolic regulator T3D-959 in patients with mild to moderate Alzheimer s disease, the PIONEER Study.
Press release content from Business Wire. The AP news staff was not involved in its creation.
AriBio Co., Ltd. Announces Last Patient Last Visit in Phase 2 Clinical Trial of AR1001 in Mild to Moderate Alzheimer’s Patients
January 21, 2021 GMT
SEONGNAM, South Korea (BUSINESS WIRE) Jan 21, 2021
AriBio Co., Ltd., a clinical-stage biopharmaceutical company based in South Korea, announced today, 21 st of January 2021, the completion of last patient last visit in a Phase 2 study of AR1001. AR1001 is a first-in-class, orally dosed investigational drug for mild to moderate Alzheimer’s disease. A total of 210 patients were enrolled, and 171 (81.4%) subjects completed 6-month dosing in the study.